More help for patients with less severe heart failure

Abstract

Prescribe a mineralocorticoid-receptor antagonist for patients with New York Heart Association (NYHA) Class II systolic heart failure and an ejection fraction (EF) ≤30%. Eplerenone has been found to decrease hospitalizations for heart failure and cardiovascular and all-cause mortality. Strength of Recommendation A: Based on one high-quality randomized controlled trial (RCT).